Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of PCS499 MR Formulations vs Trental in Healthy Subjects
NCT03836222Phase 1Completed
- Sponsor
- Processa Pharmaceuticals, Inc.
- Start
- Feb 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PCS-499 in necrobiosis lipoidica (NLD) (7 arms), sponsored by Processa Pharmaceuticals, Inc. Primary endpoint: Maximum plasma concentrations at 24 hours. Started Feb 2018; status: completed.
02
Drugs
PCS-499
03
Conditions
necrobiosis lipoidica (NLD)
Beyond the preview
Go deeper on NCT03836222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836222.